BEIGENE (06160) JPM2025 releases good news, multiple international investment banks continue to be optimistic about the company's prospects.

Recently, many investment banks such as Goldman Sachs Group, Inc., CMB International, Pu Yin International, and Nomura Securities have released their latest research reports, successively raising the target price of BEIGENE (ONC.US, 06160, 688235.SH) and giving a "buy" rating, continuing to be optimistic about the company's prospects, stating that it has reached a key turning point where annual operational profit has turned positive and innovative products have emerged in batches in the FIC/BIC Potential. Among them, Goldman Sachs Group, Inc. has raised BEIGENE's 12-month target price for its US shares from the previous 308.82 US dollars to 319.76 US dollars, and the A-share target price from 244.59 RMB to 256.76 RMB, reflecting a high recognition of BEIGENE's global market layout, research and development strength, and commercialization potential of its products. In their latest research report, institutions pointed out that BEIGENE continues to make significant progress across its product portfolio, with improved financial conditions and broad prospects in early-stage research pipelines, with Zebutinib performing well as a leading asset in the market. Many institutions are optimistic about BEIGENE's outstanding performance in the industry and future growth space, raising the company's target price and maintaining optimistic expectations for its product value enhancement and future profit growth. Public information shows that from January 13th to January 16th, at the 43rd J.P. Morgan Healthcare Conference (referred to as the "JPM Conference"), BEIGENE presented its main directions for its 2025 strategic planning to the global industry, with the company continuing to strengthen and consolidate its leadership in the field of hematology and advance a series of oncology research pipelines. By 2025, aiming to break even, in-depth layout in the field of hematologic tumors At the 2025 JPM Conference, BEIGENE's management team provided guidance on WINOX for the first time, expecting to achieve GAAP break-even operating profit by 2025, one year ahead of market expectations. BEFORE, BEIGENE had achieved Non-GAAP operating profits for two consecutive quarters (profits of 65.63 million/48.46 million USD in 3Q24/2Q24 respectively). Institutions pointed out that in the $12 billion CLL market, the company's core product, Zebutinib, has ranked first in new patient prescriptions in the United States. In the first three quarters of 2024, Zebutinib's global sales exceeded 12.9 billion RMB, totaling approximately 1.8 billion USD, continuing to surpass the company's milestone of achieving the "billion-dollar molecule" in a single ye...Realize the stability and gradual decrease of the sales cost rate. With the core product consistently contributing revenue and clear sales expectations for the backup pipeline, the sustainable profit path of the company has become clear.Hola, cmo ests?